McKesson - MCK Stock Forecast, Price & News

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Stock Performance

Shares of NYSE:MCK traded up $6.44 during mid-day trading on Friday, hitting $365.20. 769,745 shares of the stock were exchanged, compared to its average volume of 953,487. The company has a market cap of $52.49 billion, a P/E ratio of 38.60, a PEG ratio of 1.48 and a beta of 0.63. McKesson has a twelve month low of $193.89 and a twelve month high of $365.40. The stock's fifty day simple moving average is $327.38 and its two-hundred day simple moving average is $309.89.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Thursday, September 1st will be given a $0.54 dividend. This is an increase from McKesson's previous quarterly dividend of $0.47. The ex-dividend date is Wednesday, August 31st. This represents a $2.16 annualized dividend and a yield of 0.59%. McKesson's payout ratio is presently 19.87%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MCK shares. Cowen increased their target price on shares of McKesson to $384.00 in a research note on Tuesday. Cowen boosted their price objective on McKesson from $325.00 to $361.00 and gave the company an "outperform" rating in a research report on Monday, April 18th. Credit Suisse Group upped their target price on McKesson from $377.00 to $385.00 and gave the company an "outperform" rating in a research note on Monday, August 8th. Argus downgraded shares of McKesson from a "buy" rating to a "hold" rating in a research note on Wednesday, July 6th. Finally, Robert W. Baird increased their price objective on shares of McKesson from $386.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, McKesson presently has an average rating of "Moderate Buy" and an average target price of $337.62.

Insiders Place Their Bets

In other news, EVP Thomas L. Rodgers sold 209 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $326.90, for a total value of $68,322.10. Following the completion of the sale, the executive vice president now directly owns 3,353 shares in the company, valued at $1,096,095.70. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other McKesson news, CFO Britt J. Vitalone sold 27,281 shares of the company's stock in a transaction on Friday, May 27th. The stock was sold at an average price of $333.16, for a total transaction of $9,088,937.96. Following the transaction, the chief financial officer now owns 13,693 shares of the company's stock, valued at approximately $4,561,959.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Thomas L. Rodgers sold 209 shares of the stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $326.90, for a total value of $68,322.10. Following the completion of the transaction, the executive vice president now owns 3,353 shares in the company, valued at $1,096,095.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,074 shares of company stock valued at $17,347,514. 0.21% of the stock is currently owned by corporate insiders.